Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9554260 | 0.95 | AGTR1 (0.41) | AGTR1AGTR2PPARG | |
| SCHEMBL9554388 | 0.93 | AGTR1 (0.38) | AGTR1AGTR2PPARG | |
| SCHEMBL9553635 | 0.90 | AGTR1 (0.36) | AGTR1AGTR2PPARG | |
| SCHEMBL9536245 | 0.90 | AGTR1 (0.42) | AGTR1AGTR2 | |
| SCHEMBL9035616 | 0.89 | AGTR1 (0.45) | AGTR1AGTR2PPARG | |
| SCHEMBL9530971 | 0.87 | AGTR1 (0.38) | AGTR1AGTR2 | |
| SCHEMBL9036101 | 0.87 | AGTR1 (0.52) | AGTR1AGTR2 | |
| SCHEMBL9553962 | 0.86 | AGTR1 (0.49) | AGTR1AGTR2 | |
| SCHEMBL9554018 | 0.86 | AGTR1 (0.40) | AGTR1AGTR2 | |
| SCHEMBL9554092 | 0.86 | AGTR1 (0.42) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5238952-A | Treating glaucoma disorders | G. D. SEARLE & CO. (US) | 1993-08-24 | — | — | US | disclosed |
| WO-1992007834-A1 | N-SUBSTITUTED IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |
| US-5087634-A | N-substituted imidazol-2-one compounds for treatment of circulatory disorders | G. D. SEARLE & CO. (US) | 1992-02-11 | — | — | US | disclosed |